Sanofi And Amgen Make The Case For OX40 Drugs In Atopic Dermatitis
Two Therapies That Could Rival Dupixent
Executive Summary
As the European Academy of Dermatology and Venerology congress closed its doors, two OX40 atopic dermatitis drugs from Sanofi and Amgen/Kyowa Kirin caught the eye.
You may also be interested in...
Almirall On Alert As Lebrikizumab Approval Date Approaches
The Barcelona-based group is confident that Lilly-partnered lebrikizumab has the potential to become a best-in-class treatment for atopic dermatitis and take market share from Sanofi’s blockbuster Dupixent.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.